Glioblastoma: Pathogenetic, Diagnostic and Therapeutic Perspectives

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 171

Special Issue Editor


E-Mail Website
Guest Editor
Vagelos College of Physicians and Surgeons, New York, NY, USA
Interests: brain tumor

Special Issue Information

Dear Colleagues,

Glioblastoma (GBM) is a highly aggressive and invasive tumor that targets the central nervous system (CNS), boasting the lowest survival rate among CNS tumors with a median survival time of only 12–15 months. Its treatment protocol involves surgical resection, followed by fractionated radiotherapy and concurrent/adjuvant chemotherapy using temozolomide. Despite these clinical interventions, recurrence is prevalent, occurring in over 80% of cases at the resection cavity's edge within months post-treatment. This high recurrence rate and the tumor's location underscore the pressing need for a deeper understanding of therapeutic strategies.

An enhanced comprehension of GBM's molecular and cellular heterogeneity can not only refine subgroup categorization for precise diagnosis but also pave the way for targeted therapy success. Targeting the Warburg effect presents a promising avenue for GBM treatment due to its metabolic adaptability. Moreover, employing various immunotherapeutic approaches such as checkpoint inhibitors, vaccines, CAR-modified NK or T cells, and oncolytic virotherapy aims to bolster the immune response against GBM. Additionally, efforts to breach the blood–brain barrier (BBB) using nanotherapies (targeting GB cellular receptors or opening the BBB) or non-ionizing energies (high/low-intensity focused ultrasounds) offer potential breakthroughs to overcome current therapy limitations.

This Special Issue aims to delve into the pathophysiological mechanisms driving glioblastoma, uncover potential therapeutic targets, and explore advanced methodologies that hold promise in combating this lethal disease.

Dr. Thi Thu Trang Nguyen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery methods (TTFields, nanoparticles)
  • immunotherapy
  • oncolytic virotherapy
  • cell metabolism (glycolysis, OXPHOS, fatty acid oxidation)
  • epigenetic
  • biomarkers
  • gene therapy (CRISPR/Cas9)

Published Papers

This special issue is now open for submission.
Back to TopTop